Edition:
India

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

88.92EUR
19 Jan 2018
Change (% chg)

€0.68 (+0.77%)
Prev Close
€88.24
Open
€88.50
Day's High
€88.92
Day's Low
€88.22
Volume
32,708
Avg. Vol
52,962
52-wk High
€90.24
52-wk Low
€46.31

Chart for

About

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and... (more)

Overall

Beta: 0.86
Market Cap(Mil.): €5,145.75
Shares Outstanding(Mil.): 62.34
Dividend: 0.72
Yield (%): 0.87

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Stada Agrees To Early Termination Of License Agreement With Sanofi

* STADA AGREES TO EARLY TERMINATION OF LICENSE AGREEMENT WITH SANOFI FOR HEAD LICE LOTION HEDRIN Further company coverage: (Gdynia Newsroom)

18 Jan 2018

Nestle frontrunner for Merck KGaA's consumer health business: Bloomberg

ZURICH Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

10 Jan 2018

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

ZURICH, Jan 10 Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

10 Jan 2018

BRIEF-Stada Says Domination And Profit And Loss Transfer Agreement Concluded

* DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT PURSUANT TO SECTIONS 291 ET SEQQ. AKTG CONCLUDED BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH

19 Dec 2017

Germany's Merck in fresh bid to enter U.S. MS pill market

FRANKFURT Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated its ambitions almost seven years ago.

15 Dec 2017

UPDATE 2-Germany's Merck in fresh bid to enter U.S. MS pill market

* Unit head Garijo says targeting most severely affected patients

15 Dec 2017

Perrigo lines up bid for Merck's consumer health unit: sources

LONDON/FRANKFURT Generic drugmaker Perrigo has decided to enter the fray for Merck KGaA's consumer health unit, sources told Reuters, and is preparing an indicative offer for the $4.7 billion business ahead of a deadline on Friday.

15 Dec 2017

UPDATE 1-Perrigo lines up bid for Merck's consumer health unit -sources

* Perrigo to submit non-binding offer for Merck KGaA's OTC unit

15 Dec 2017

Perrigo preparing non-binding bid for Merck KgaA's consumer health unit -sources

LONDON/FRANKFURT, Dec 14 U.S. drugmaker Perrigo has decided to enter the fray for Merck KgaA's consumer health unit, sources told Reuters on Thursday, and is preparing an indicative offer for the $4.7 billion business ahead of the Dec. 15 deadline.

14 Dec 2017

Swiss stocks - Factors to watch on Dec 4

ZURICH, Dec 4 The Swiss blue-chip SMI was seen opening 1 percent higher at 9,365 points on Monday, according to premarket indications by bank Julius Baer .

04 Dec 2017

Earnings vs. Estimates